Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans
- PMID: 8006323
- DOI: 10.1007/BF03344953
Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans
Abstract
The availability of a new potent and selective serotonin-S2 antagonist, ritanserin (RIT), encouraged us to further investigate the effect of serotonin on the basal secretion of anterior pituitary hormones in normal humans. Administered in a single 30-mg dose to group 1 consisting of 10 normal women, RIT failed to affect the baseline LH, FSH, GH or TSH levels. In group 2 consisting of 20 normal subjects (ten males and ten females), the same dose of RIT decreased in parallel both ACTH and cortisol levels but only at 180 min. Group 3 consisting of 8 normal men was studied on three separate occasions seven days apart: each subject received graded doses of 10 mg, 20 mg and 30 mg RIT. The mean baseline PRL concentration at 180 min as well as the net integrated area under the hormone curve (nAUC) decreased only after the highest dose, while the baseline cortisol concentrations at 180 min as well as the corresponding nAUC values displayed a clear dose-dependent response. The findings indicated the serotonin-S2 receptors to be only partially involved in the basal secretion of ACTH in normal humans.
Similar articles
-
Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.J Endocrinol Invest. 1995 Jun;18(6):427-30. doi: 10.1007/BF03349740. J Endocrinol Invest. 1995. PMID: 7594236 Clinical Trial.
-
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans.Eur J Endocrinol. 1995 Sep;133(3):300-4. doi: 10.1530/eje.0.1330300. Eur J Endocrinol. 1995. PMID: 7581945
-
Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans.Metabolism. 1989 Dec;38(12):1179-82. doi: 10.1016/0026-0495(89)90156-x. Metabolism. 1989. PMID: 2574405
-
Neuroendocrine consequences of chemical indolectomy.Ann N Y Acad Sci. 1978 Jun 12;305:387-98. doi: 10.1111/j.1749-6632.1978.tb31536.x. Ann N Y Acad Sci. 1978. PMID: 212997 Review. No abstract available.
-
The role of serotonin and dopamine in hypothalamic-pituitary function.Clin Endocrinol (Oxf). 1977 Oct;7(4):325-41. doi: 10.1111/j.1365-2265.1977.tb01331.x. Clin Endocrinol (Oxf). 1977. PMID: 200382 Review. No abstract available.
Cited by
-
Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.J Endocrinol Invest. 1995 Jun;18(6):427-30. doi: 10.1007/BF03349740. J Endocrinol Invest. 1995. PMID: 7594236 Clinical Trial.
-
Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release.J Psychopharmacol. 2010 Jul;24(7):1079-88. doi: 10.1177/0269881109103090. Epub 2009 Mar 20. J Psychopharmacol. 2010. PMID: 19304867 Free PMC article.
-
Ziprasidone decreases cortisol excretion in healthy subjects.Br J Clin Pharmacol. 2005 Sep;60(3):330-6. doi: 10.1111/j.1365-2125.2005.02431.x. Br J Clin Pharmacol. 2005. PMID: 16120074 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources